114 related articles for article (PubMed ID: 34085825)
1. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells
Slusarczyk M; Serpi M; Ghazaly E; Kariuki BM; McGuigan C; Pepper C
J Med Chem; 2021 Jun; 64(12):8179-8193. PubMed ID: 34085825
[TBL] [Abstract][Full Text] [Related]
2. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M; Lopez MH; Balzarini J; Mason M; Jiang WG; Blagden S; Thompson E; Ghazaly E; McGuigan C
J Med Chem; 2014 Feb; 57(4):1531-42. PubMed ID: 24471998
[TBL] [Abstract][Full Text] [Related]
3. The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms
Schwenzer H; De Zan E; Elshani M; van Stiphout R; Kudsy M; Morris J; Ferrari V; Um IH; Chettle J; Kazmi F; Campo L; Easton A; Nijman S; Serpi M; Symeonides S; Plummer R; Harrison DJ; Bond G; Blagden SP
Clin Cancer Res; 2021 Dec; 27(23):6500-6513. PubMed ID: 34497073
[TBL] [Abstract][Full Text] [Related]
4. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
McGuigan C; Murziani P; Slusarczyk M; Gonczy B; Vande Voorde J; Liekens S; Balzarini J
J Med Chem; 2011 Oct; 54(20):7247-58. PubMed ID: 21892829
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
Boyer SH; Sun Z; Jiang H; Esterbrook J; Gómez-Galeno JE; Craigo W; Reddy KR; Ugarkar BG; MacKenna DA; Erion MD
J Med Chem; 2006 Dec; 49(26):7711-20. PubMed ID: 17181153
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
7. The effects of addition of mononucleotides on Sma nuc endonuclease activity.
Romanova J; Filimonova M
ScientificWorldJournal; 2012; 2012():454176. PubMed ID: 22654609
[TBL] [Abstract][Full Text] [Related]
8. NUC-1031 in biliary tract cancer: from bench to bedside and back?
Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 6-substituted-5-fluorouridine ProTides.
Slusarczyk M; Ferla S; Brancale A; McGuigan C
Bioorg Med Chem; 2018 Feb; 26(3):551-565. PubMed ID: 29277307
[TBL] [Abstract][Full Text] [Related]
10. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
[TBL] [Abstract][Full Text] [Related]
11. L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
Gao LJ; De Jonghe S; Daelemans D; Herdewijn P
Bioorg Med Chem Lett; 2016 May; 26(9):2142-6. PubMed ID: 27032331
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent.
Serpi M; Ferrari V; McGuigan C; Ghazaly E; Pepper C
J Med Chem; 2022 Dec; 65(23):15789-15804. PubMed ID: 36417756
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
Tobias SC; Borch RF
J Med Chem; 2001 Dec; 44(25):4475-80. PubMed ID: 11728193
[TBL] [Abstract][Full Text] [Related]
14. New antiglioma zwitterionic pronucleotides with an FdUMP framework.
Szymanska-Michalak A; Wawrzyniak D; Framski G; Stawinski J; Barciszewski J; Kraszewski A
Eur J Med Chem; 2018 Jan; 144():682-691. PubMed ID: 29289891
[TBL] [Abstract][Full Text] [Related]
15. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.
Kempema AM; Widen JC; Hexum JK; Andrews TE; Wang D; Rathe SK; Meece FA; Noble KE; Sachs Z; Largaespada DA; Harki DA
Bioorg Med Chem; 2015 Aug; 23(15):4737-4745. PubMed ID: 26088334
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA polymerase-alpha by ara-CMP in the presence of a regulatory protein extracted from human promyelocytic leukemic cells (HL-60).
Leclerc JM; Grisé-Miron L; Labonté L
Semin Oncol; 1987 Jun; 14(2 Suppl 1):226-30. PubMed ID: 3473678
[TBL] [Abstract][Full Text] [Related]
18. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
19. Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?
García-Ramírez I; Martín-Lorenzo A; González-Herrero I; Rodriguez-Hernández G; Vicente-Dueñas C; Sánchez-García I
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27275819
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation.
Bazzanini R; Manfredini S; Durini E; Gröschel B; Cinatl J; Balzarini J; De Clercq E; Imbach JL; Périgaud C; Gosselin G
Nucleosides Nucleotides; 1999; 18(4-5):971-2. PubMed ID: 10432722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
